Quotient Bioresearch to sell bioanalytical sciences division to LGC
Acquisition will enable LGC to offer bioanalysis, materials science and reference materials
Quotient Bioresearch has agreed to sell its Bioanalytical Sciences division to LGC. No financial details were revealed.
Quotient Bioanalytical Sciences is a provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.
The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to enhance its range of products and services for the pharmaceutical sector including bioanalysis, materials science and reference materials among others.
Under the terms of the deal, Quotient and LGC will collaborate as preferred partners on the provision of bioanalytical sciences. This will enable customers to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling. The business will continue to trade under the Quotient name under its new ownership for the time being.
The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at Fordham. Jeremy Cook, MD of LGC’s Health Sciences, said Quotient Bioanalytical Sciences, is a ‘high quality business’ that complements its existing activities.
Dr Steve Pleasance, MD of Quotient Bioanalytical Sciences, added: ‘LGC’s focus on complex analytical chemistry, high quality science and service delivery make it a natural home for our business. Both our organisations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.’